FENC Fennec Pharmaceuticals Inc.
USHealthcareAs of 2026-07-10 16:00
Why FENC matters now
Fennec Pharmaceuticals Inc. (FENC) is a US stock in Healthcare. The latest InvestLog snapshot shows $10.49 with +1.75% on the session and $299.8M in market capitalization; recent performance reads 1-month -7.17% and YTD +17.66%.
The latest financial table shown here is Q1 2026, with revenue of $15.1M, net income of $201.0K, and EPS of $0.01. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.2%.
The latest indexable market news headline is "Is the Options Market Predicting a Spike in Adherex Technologies Stock?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $17.00; recent insider activity includes RALLIS CHRIS A filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
8.26
P/S
5.08
EV/EBITDA
-32.79
DCF Value
$-6.80
FCF Yield
-2.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.2%
Operating Margin
-11.0%
Net Margin
-16.4%
ROE
-55.1%
ROA
-11.7%
ROIC
-9.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.1M | $201.0K | $0.01 |
| Q4 2025 | $13.8M | $-4.8M | $-0.17 |
| FY 2025 | $44.6M | $-9.7M | $-0.36 |
| Q3 2025 | $12.5M | $-638.0K | $-0.02 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$17.00
Target (Median)
$17.00
Target Range
$16.00 - $18.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.08
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.